Medical/Pharmaceuticals
Introducing the VARON VP-8G: A Smarter, Lighter Portable Oxygen Concentrator Built for Life on the Move
NEW YORK, July 15, 2025 /PRNewswire/ -- For those who need reliable oxygen
support without compromising mobility,VARON
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Nietham...
Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors
TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...
Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, onc...
Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the s...
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP34...
LG Debuts Next-Generation Precision Medical AI
Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ -- LG AI Research announced on July 9 the official launch of 'EXAONE Path 2.0', its next-generation precision medical AI model. Followin...
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics,...
Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
PALO ALTO, Calif., July 10, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace,
Inc. (https://ipeace.com/en/
Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
SHANGHAI, July 9, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 ...
GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability
PISCATAWAY, N.J., July 9, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment plat...
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of d...
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of...
LakeShore Biopharma Announces US$15 Million Private Placement Financing
BEIJING, July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today ...
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently provided updates to investors on the st...
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] * STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially availa...
WuXi AppTec Receives MSCI ESG AAA Leader Rating
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its lates...
Coreline Soft and Temple Health to Co-Host Webinar on AI-Driven Lung Cancer Screening and Improving Patient Outcomes
* Real-world outcomes: How AI improved both diagnostic efficiency, early
detection, and comorbidity detection
* Deep dive into the precision technology of the FDA-cleared platform, AVIEW
LCS Plus PHILADELPHIA and SEOUL, South Korea, July 7, 2025 /PRNewswire/ --
Coreline Soft
The Voices of Persons Affected by Hansen's Disease Move the World: 3rd Global Forum Held in Bali, Indonesia
TOKYO, July 7, 2025 /PRNewswire/ -- In a landmark gathering that placed lived experience at the center of global health discourse, the 3rd Global Forum of People's Organizations on Hansen's Disease was held inBali, Indonesia, from July 4 to 6, 2025. Organized by the Sasakawa Leprosy (Hansen's Dis...
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 261 media titles]
2026-10-06 11:40